Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant

Sam D. Sanderson, Srinivasa R. Cheruku, Maniyan P. Padmanilayam, Jonathan L Vennerstrom, Geoffrey Milton Thiele, Matthew I. Palmatier, Rick A Bevins

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

This paper describes the synthesis of a nicotine hapten (Nic) that possesses a carboxyl sidearm functional group allowing for conjugation to a peptide via amide bond formation. Nic was attached to the N-terminal amino group of a 19-residue peptide composed of a conformationally biased agonist of human C5a (YSFKPMPLaR), which is used as a molecular adjuvant and a B cell epitope of human MUC1 glycoprotein (YKQGGFLGL) to yield a peptide-based nicotine vaccine, NicYKQGGFLGLYSFKPMPLaR. Rats immunized with this vaccine were significantly less sensitive to behavioral effects (a Pavlovian discrimination task) induced by their exposure to high concentrations of nicotine (0.4 mg/kg) relative to their non-vaccinated counterparts. The attenuation of these nicotine-induced behavioral effects emanated from the presence of nicotine-specific antibodies (Abs) that were present in the sera of vaccinated rats even after their repeated exposure to high concentrations of nicotine during the time required to perform the behavioral assays. These results suggest that immunization with NicYKQGGFLGLYSFKPMPLaR in the absence of adjuvant is an effective means of inducing a nicotine-specific Ab response, which is capable of attenuating nicotine-induced behavioral/psychoactive effects.

Original languageEnglish (US)
Pages (from-to)137-146
Number of pages10
JournalInternational Immunopharmacology
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Subunit Vaccines
Nicotine
Immunization
Peptides
Vaccines
B-Lymphocyte Epitopes
Haptens
Amides
Glycoproteins
Antibodies
Serum

Keywords

  • Conformationally biased C5a agonist
  • Molecular adjuvant
  • Peptide-based nicotine vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. / Sanderson, Sam D.; Cheruku, Srinivasa R.; Padmanilayam, Maniyan P.; Vennerstrom, Jonathan L; Thiele, Geoffrey Milton; Palmatier, Matthew I.; Bevins, Rick A.

In: International Immunopharmacology, Vol. 3, No. 1, 01.01.2003, p. 137-146.

Research output: Contribution to journalArticle

@article{54b5dd2903404ac690593a42474d6801,
title = "Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant",
abstract = "This paper describes the synthesis of a nicotine hapten (Nic) that possesses a carboxyl sidearm functional group allowing for conjugation to a peptide via amide bond formation. Nic was attached to the N-terminal amino group of a 19-residue peptide composed of a conformationally biased agonist of human C5a (YSFKPMPLaR), which is used as a molecular adjuvant and a B cell epitope of human MUC1 glycoprotein (YKQGGFLGL) to yield a peptide-based nicotine vaccine, NicYKQGGFLGLYSFKPMPLaR. Rats immunized with this vaccine were significantly less sensitive to behavioral effects (a Pavlovian discrimination task) induced by their exposure to high concentrations of nicotine (0.4 mg/kg) relative to their non-vaccinated counterparts. The attenuation of these nicotine-induced behavioral effects emanated from the presence of nicotine-specific antibodies (Abs) that were present in the sera of vaccinated rats even after their repeated exposure to high concentrations of nicotine during the time required to perform the behavioral assays. These results suggest that immunization with NicYKQGGFLGLYSFKPMPLaR in the absence of adjuvant is an effective means of inducing a nicotine-specific Ab response, which is capable of attenuating nicotine-induced behavioral/psychoactive effects.",
keywords = "Conformationally biased C5a agonist, Molecular adjuvant, Peptide-based nicotine vaccine",
author = "Sanderson, {Sam D.} and Cheruku, {Srinivasa R.} and Padmanilayam, {Maniyan P.} and Vennerstrom, {Jonathan L} and Thiele, {Geoffrey Milton} and Palmatier, {Matthew I.} and Bevins, {Rick A}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S1567-5769(02)00260-6",
language = "English (US)",
volume = "3",
pages = "137--146",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant

AU - Sanderson, Sam D.

AU - Cheruku, Srinivasa R.

AU - Padmanilayam, Maniyan P.

AU - Vennerstrom, Jonathan L

AU - Thiele, Geoffrey Milton

AU - Palmatier, Matthew I.

AU - Bevins, Rick A

PY - 2003/1/1

Y1 - 2003/1/1

N2 - This paper describes the synthesis of a nicotine hapten (Nic) that possesses a carboxyl sidearm functional group allowing for conjugation to a peptide via amide bond formation. Nic was attached to the N-terminal amino group of a 19-residue peptide composed of a conformationally biased agonist of human C5a (YSFKPMPLaR), which is used as a molecular adjuvant and a B cell epitope of human MUC1 glycoprotein (YKQGGFLGL) to yield a peptide-based nicotine vaccine, NicYKQGGFLGLYSFKPMPLaR. Rats immunized with this vaccine were significantly less sensitive to behavioral effects (a Pavlovian discrimination task) induced by their exposure to high concentrations of nicotine (0.4 mg/kg) relative to their non-vaccinated counterparts. The attenuation of these nicotine-induced behavioral effects emanated from the presence of nicotine-specific antibodies (Abs) that were present in the sera of vaccinated rats even after their repeated exposure to high concentrations of nicotine during the time required to perform the behavioral assays. These results suggest that immunization with NicYKQGGFLGLYSFKPMPLaR in the absence of adjuvant is an effective means of inducing a nicotine-specific Ab response, which is capable of attenuating nicotine-induced behavioral/psychoactive effects.

AB - This paper describes the synthesis of a nicotine hapten (Nic) that possesses a carboxyl sidearm functional group allowing for conjugation to a peptide via amide bond formation. Nic was attached to the N-terminal amino group of a 19-residue peptide composed of a conformationally biased agonist of human C5a (YSFKPMPLaR), which is used as a molecular adjuvant and a B cell epitope of human MUC1 glycoprotein (YKQGGFLGL) to yield a peptide-based nicotine vaccine, NicYKQGGFLGLYSFKPMPLaR. Rats immunized with this vaccine were significantly less sensitive to behavioral effects (a Pavlovian discrimination task) induced by their exposure to high concentrations of nicotine (0.4 mg/kg) relative to their non-vaccinated counterparts. The attenuation of these nicotine-induced behavioral effects emanated from the presence of nicotine-specific antibodies (Abs) that were present in the sera of vaccinated rats even after their repeated exposure to high concentrations of nicotine during the time required to perform the behavioral assays. These results suggest that immunization with NicYKQGGFLGLYSFKPMPLaR in the absence of adjuvant is an effective means of inducing a nicotine-specific Ab response, which is capable of attenuating nicotine-induced behavioral/psychoactive effects.

KW - Conformationally biased C5a agonist

KW - Molecular adjuvant

KW - Peptide-based nicotine vaccine

UR - http://www.scopus.com/inward/record.url?scp=0037238710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037238710&partnerID=8YFLogxK

U2 - 10.1016/S1567-5769(02)00260-6

DO - 10.1016/S1567-5769(02)00260-6

M3 - Article

VL - 3

SP - 137

EP - 146

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 1

ER -